BioCentury
ARTICLE | Company News

AstraZeneca, Allergan deal

February 8, 2016 8:00 AM UTC

The companies partnered to develop and commercialize ATM-AVI to treat metallo-beta-lactamase-producing Gram-negative bacterial infections. Allergan will have commercialization rights in the U.S. and Canada, and AstraZeneca will retain rights in all other countries. ATM-AVI was developed under a partnership between AZ and the U.S. Biomedical Medical Advanced Research and Development Authority (BARDA). Allergan said EU’s Innovative Medicines Initiative (IMI) is supporting a European Phase II trial of the candidate and will join BARDA and AZ in supporting Phase III development. ...